In a report issued on July 7, Brian Abrahams from RBC Capital maintained a Hold rating on Intercept Pharma (ICPT – Research Report), with a price target of $16.00. The company’s shares closed last Friday at $15.35.
According to TipRanks.com, Abrahams is a 1-star analyst with an average return of -1.0% and a 46.5% success rate. Abrahams covers the Healthcare sector, focusing on stocks such as Intra-Cellular Therapies, Karyopharm Therapeutics, and Vertex Pharmaceuticals.
Intercept Pharma has an analyst consensus of Moderate Buy, with a price target consensus of $28.63, implying a 95.2% upside from current levels. In a report issued on July 7, Oppenheimer also maintained a Hold rating on the stock with a $16.00 price target.
Based on Intercept Pharma’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $88.58 million and GAAP net loss of $17.28 million. In comparison, last year the company earned revenue of $81.66 million and had a GAAP net loss of $40.42 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Intercept Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of novel therapeutics in treating chronic liver diseases. Its product pipeline is OCALIVA which is used for the treatment of primary biliary cholangitis, nonalcoholic steatohepatitis, primary sclerosing cholangitis, and biliary atresia. The company was founded by Mark E. Pruzanski and Roberto Pellicciari on September 4, 2002 and is headquartered in New York, NY.
Read More on ICPT: